Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.
about
Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasionA novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4AControl of Kaposi's sarcoma-associated herpesvirus reactivation induced by multiple signalsTargeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma.Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.Novel therapeutic targets in myeloma bone disease.Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma.RETRACTED: The effects of dexamethasone on the proliferation and apoptosis of human ovarian cancer cells induced by paclitaxel.The molecular classification of multiple myelomaGlucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1).Novel therapeutic approaches for multiple myeloma.The use of genetic microarray analysis to classify and predict prognosis in haematological malignancies.A novel role for Bruton's tyrosine kinase in hepatocyte growth factor-mediated immunoregulation of dendritic cells.Glucocorticoid elevation of dexamethasone-induced gene 2 (Dig2/RTP801/REDD1) protein mediates autophagy in lymphocytes.Targeting signalling pathways for the treatment of multiple myeloma.Extracellular matrix in bone marrow can mediate drug resistance in myeloma.Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myelomaGlucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.Thalidomide and dexamethasone: therapy for multiple myeloma.Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma.Gene expression profiling of leukemic cells and primary thymocytes predicts a signature for apoptotic sensitivity to glucocorticoidsCombination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors.Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1The molecular characterization and clinical management of multiple myeloma in the post-genome era.Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myelomaPreclinical studies of novel targeted therapies.Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expressionThe epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.Bruton tyrosine kinase (BTK) and its role in B-cell malignancy.Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing.Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma.MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
P2860
Q24538826-0E1FDB76-B4DD-40C0-8B53-276AA4F8FDF7Q24623285-92DBBC11-99F5-4D2C-9D79-63F526D72410Q28478842-41176508-A96B-4B90-835F-F9AD1142C6BFQ33763765-1478AFAC-C1C2-4241-8B21-6237FDB53172Q33839840-0DEC9B0D-5740-4744-A47D-D3A254CDD837Q33846310-32C02194-BC4D-4E49-86D7-93E7B5191E99Q33941874-9E7C3C11-9780-45BB-807F-0A47D41C782CQ34022979-44C65625-287E-4EA1-9CCC-2735557EDF1BQ34025065-165716EA-B117-46CF-9198-A8AB80F7DB62Q34052565-B2ADA829-50C0-4192-A1ED-A49C327B02D1Q34355401-5CBF1BB1-55B4-44A8-8470-735F5F56EBC8Q34530992-84BB7540-21C6-476B-8CC1-01EF2A2837D7Q35002526-DFDD3335-B77A-4EB5-B4DD-0BC053EB46BCQ35170935-21C6F260-A3CC-4E59-B40E-84EE9F4DD174Q35188517-3CD0D50D-3053-438A-8247-E8BB43D768EAQ35213426-E5A7C4A6-9232-4BC5-9A9B-0030D88DBE15Q35314426-865C4443-5F2C-44C7-87CA-C380A1180A34Q36150866-8F150ED7-FF91-48C5-8099-FC064A9B266EQ36194659-E8CB145A-9806-478C-8DE1-FBF17F9796E8Q36206430-27623909-58DD-4D9B-B46A-FC529E9FBBA7Q36211482-ADE46F52-5E82-44C0-8DE7-33311F10E776Q36284481-722247A0-C393-4A52-850B-B35C48F55CA5Q36367811-BDFC527F-9E43-4395-919A-BFD0F549542DQ36413655-C5FDD562-BC40-4C85-A1FD-64C2E632761DQ36431877-5A5D55DC-F05B-4507-9900-6FD770E96FBCQ36589122-C598348D-6035-436B-8690-844E7BE9869DQ36835067-42FFB20E-96CB-40DC-9884-625FBA915DD3Q36915777-DCC39A11-9F5B-4B26-B744-301D292BAB79Q36939043-63EB53E4-7C6D-46C1-BB33-42CEF93E63E8Q36980287-4409B130-5F08-41D4-AEE0-E0D0C4ABBC5FQ36998210-5A91B105-27AC-4F5A-BC00-646F38415E13Q37079785-A5870884-6138-45E3-90AF-287D83548314Q37166798-14467938-8564-4A01-8DBD-032D46925C42Q37946246-DE7D17E3-26DC-4F38-8406-42E060827717Q37997075-F727FF88-6B62-47B3-AD52-DE004C9FCDC9Q38101343-8A5C6345-CD1D-451C-860C-63E403D4E4D2Q38436359-3C9F783D-EFEA-4091-9761-6F5CD4641D5AQ38808084-245BDC95-3B46-44DE-BF9A-4376B64A4D25Q38862552-ADD1E487-FC54-4AE4-969B-1970FA138512Q39024879-8485440D-90CE-4A8C-8B0D-882B8093A42E
P2860
Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Identification of genes regula ...... using oligonucleotide arrays.
@en
type
label
Identification of genes regula ...... using oligonucleotide arrays.
@en
prefLabel
Identification of genes regula ...... using oligonucleotide arrays.
@en
P2093
P2860
P356
P1433
P1476
Identification of genes regula ...... using oligonucleotide arrays.
@en
P2093
Daniel Auclair
Deepak Gupta
Dharminder Chauhan
Elisabeth K Robinson
Klaus Podar
Lan Bo Chen
Nancy Krett
Nikhil C Munshi
Robert L Schlossman
P2860
P2888
P304
P356
10.1038/SJ.ONC.1205205
P407
P577
2002-02-01T00:00:00Z
P5875
P6179
1042576999